These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35157758)

  • 21. Opinion & Special Article: Glioma Classification: How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report.
    van der Meulen M; Ramos RC; Mason WP; Von Deimling A; Maas SLN
    Neurology; 2022 Nov; 99(20):903-908. PubMed ID: 36240081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Considerations in the Treatment of Grade 3 Gliomas.
    Jo J; Schiff D
    Curr Treat Options Oncol; 2022 Sep; 23(9):1219-1232. PubMed ID: 35913658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
    Zhang Y; Lucas CG; Young JS; Morshed RA; McCoy L; Oberheim Bush NA; Taylor JW; Daras M; Butowski NA; Villanueva-Meyer JE; Cha S; Wrensch M; Wiencke JK; Lee JC; Pekmezci M; Phillips JJ; Perry A; Bollen AW; Aghi MK; Theodosopoulos P; Chang EF; Hervey-Jumper SL; Berger MS; Clarke JL; Chang SM; Molinaro AM; Solomon DA
    Neuro Oncol; 2022 Oct; 24(10):1749-1762. PubMed ID: 35395677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.
    Richardson TE; Walker JM; Hambardzumyan D; Brem S; Hatanpaa KJ; Viapiano MS; Pai B; Umphlett M; Becher OJ; Snuderl M; McBrayer SK; Abdullah KG; Tsankova NM
    Acta Neuropathol; 2024 Jul; 148(1):5. PubMed ID: 39012509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraoperative detection of IDH-mutant glioma using fluorescence lifetime imaging.
    Noble Anbunesan S; Alfonso-Garcia A; Zhou X; Bec J; Lee HS; Jin LW; Bloch O; Marcu L
    J Biophotonics; 2023 Apr; 16(4):e202200291. PubMed ID: 36510639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas.
    Blanco-Carmona E; Narayanan A; Hernandez I; Nieto JC; Elosua-Bayes M; Sun X; Schmidt C; Pamir N; Özduman K; Herold-Mende C; Pagani F; Cominelli M; Taranda J; Wick W; von Deimling A; Poliani PL; Rehli M; Schlesner M; Heyn H; Turcan Ş
    Cell Rep Med; 2023 Nov; 4(11):101249. PubMed ID: 37883975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proton MR spectroscopy shows improved performance to segregate high-grade astrocytoma subgroups when defined with the new 2021 World Health Organization classification of central nervous system tumors.
    Majós C; Pons-Escoda A; Naval P; Güell A; Lucas A; Vidal N; Cos M; Bruna J
    Eur Radiol; 2024 Apr; 34(4):2174-2182. PubMed ID: 37740778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MUC17 mutations and methylation are associated with poor prognosis in adult-type diffuse glioma patients.
    Machado GC; Ferrer VP
    J Neurol Sci; 2023 Sep; 452():120762. PubMed ID: 37562166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A map of the spatial distribution and tumour-associated macrophage states in glioblastoma and grade 4 IDH-mutant astrocytoma.
    Yin W; Ping YF; Li F; Lv SQ; Zhang XN; Li XG; Guo Y; Liu Q; Li TR; Yang LQ; Yang KD; Liu YQ; Luo CH; Luo T; Wang WY; Mao M; Luo M; He ZC; Cao MF; Chen C; Miao JY; Zeng H; Wang C; Zhou L; Yang Y; Yang X; Wang QH; Feng H; Shi Y; Bian XW
    J Pathol; 2022 Oct; 258(2):121-135. PubMed ID: 35723032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.
    Chen W; Guo S; Wang Y; Shi Y; Guo X; Liu D; Li Y; Wang Y; Xing H; Xia Y; Li J; Wu J; Liang T; Wang H; Liu Q; Jin S; Qu T; Li H; Yang T; Zhang K; Wang Y; Ma W
    Cancer Med; 2023 Sep; 12(18):18666-18678. PubMed ID: 37667984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
    Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
    Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
    Shirai Y; Ueno T; Kojima S; Ikeuchi H; Kitada R; Koyama T; Takahashi F; Takahashi K; Ichimura K; Yoshida A; Sugino H; Mano H; Narita Y; Takahashi M; Kohsaka S
    J Neurooncol; 2024 Mar; 167(1):75-88. PubMed ID: 38363490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era.
    Pinson H; Silversmit G; Vanhauwaert D; Vanschoenbeek K; Okito JK; De Vleeschouwer S; Boterberg T; De Gendt C
    Neuro Oncol; 2024 Jan; 26(1):191-202. PubMed ID: 37651614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular differences between IDH-wildtype glioblastoma and astrocytoma IDH-mutant grade 4 at imaging and transcriptomic levels.
    Álvarez-Torres MDM; López-Cerdán A; Andreu Z; de la Iglesia Vayá M; Fuster-Garcia E; García-García F; García-Gómez JM
    NMR Biomed; 2023 Nov; 36(11):e5004. PubMed ID: 37482922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting IDH-Mutant Glioma.
    Miller JJ
    Neurotherapeutics; 2022 Oct; 19(6):1724-1732. PubMed ID: 35476295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.
    Wollring MM; Werner JM; Ceccon G; Lohmann P; Filss CP; Fink GR; Langen KJ; Galldiks N
    J Neurooncol; 2023 May; 162(3):481-488. PubMed ID: 36577872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultra-high b-value DWI accurately identifies isocitrate dehydrogenase genotypes and tumor subtypes of adult-type diffuse gliomas.
    Wang X; Shu X; He P; Cai Y; Geng Y; Hu X; Sun Y; Xiao H; Zheng W; Song Y; Xue Y; Jiang R
    Eur Radiol; 2024 Oct; 34(10):6751-6762. PubMed ID: 38528135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center.
    Qiu X; Gao J; Hu J; Yang J; Hu W; Huang Q; Zhang H; Lu JJ; Kong L
    J Neurooncol; 2023 May; 162(3):503-514. PubMed ID: 36583815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adult-type Diffuse Gliomas.
    de la Fuente MI
    Continuum (Minneap Minn); 2023 Dec; 29(6):1662-1679. PubMed ID: 38085893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [World Health Organization Classification of Central Nervous System Tumours, 5
    Ichimura K
    No Shinkei Geka; 2023 Mar; 51(2):349-363. PubMed ID: 37055056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.